Provide supporting evidence for a diagnosis of type III hyperlipoproteinemia for evaluation of premature coronary heart disease.
Polymerase Chain Reaction/Fluorescence Monitoring
Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Plasma or serum. Heparinized specimens.
This test is not recommended for nonsymptomatic patients under 18 years of age.
Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 month
Homozygous APOE e3 (e3/e3): This genotype is the most common (normal) genotype.
Background Information for Apolipoprotein E (APOE) Genotyping, Cardiovascular Risk
Characteristics: Hyperlipoproteinemia III (HPL III) is characterized by increased cholesterol and triglyceride levels, presence of B-VLDL, xanthomas, and premature vascular disease including coronary heart disease (CHD) and peripheral artery disease.
Incidence of HPL III: Approximately 1 in 5,000.
Inheritance of HPL III: Multifactorial; greater than 90 percent of affected individuals are homozygous for the e2 allele but other factors such as diabetes and hypothyroidism also play a large role in development of disease.
Penetrance: 1 to 5 percent of individuals homozygous for the e2 will develop HPL III.
Cause: 2 copies of the e2 allele provides supporting evidence for a diagnosis of HPL III in a symptomatic individual but e2 homozygosity is neither necessary nor sufficient for HPL III.
Variants Tested: APOE gene alleles, e2 (c.388T, p.130Cys and c.526C>T, p.Arg176Cys), e3 (c.388T, p.130Cys and c.526C, p.176Arg ), e4 (c.388T>C, p.Cys130Arg and c.526C, p.176Arg).
Clinical Sensitivity: 90 percent of individuals with HPL III are homozygous for the e2 variant.
Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring using hybridization probes.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Only the e2, e3 and e4 variants will be detected. Rare isoforms of APOE will not be detected. If rare alleles are suspected, phenotyping by isoelectric focusing may be indicated. Diagnostic errors can occur due to rare sequence variations.
Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
|Component Test Code*||Component Chart Name||LOINC|
|2013339||APOE Cardiovascular Risk, Genotype|
- ApoE 2 mutations
- ApoE cardiac risk
- ApoLipoprotein E Genotype